Literature DB >> 818378

Gold-induced enterocolitis. Case report and literature review.

H B Stein, M B Urowitz.   

Abstract

A case of gold-induced enterocolitis and a review of the literature are reported. Gold-induced enterocolitis appears to be an uncommon reaction, occurring in middle-aged females who have received low doses of gold preparations. Symptoms may include fever, nausea, vomiting, abdominal cramps, and diarrhea with or without blood. The whole of the gastrointestinal tract may be involved and fatal cases occur. The diagnosis of a primary enteropathic arthropathy may be suggested. Cessation of gold, glucocorticoids and supportive therapy are indicated. The mechanism of the reaction is still unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 818378

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Gold induced enterocolitis.

Authors:  C W Jackson; N Y Haboubi; P J Whorwell; P F Schofield
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

Review 2.  Adverse reactions with oral and parenteral gold preparations.

Authors:  E C Tozman; N L Gottlieb
Journal:  Med Toxicol       Date:  1987 May-Jun

3.  Gold induced enterocolitis complicated by cytomegalovirus infection: a previously unrecognised association.

Authors:  V Wong; J Wyatt; F Lewis; P Howdle
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

4.  Gold colitis, therapy and confirmation of mucosal recovery by measurement of rectal potential difference.

Authors:  G J Huston
Journal:  Postgrad Med J       Date:  1980-12       Impact factor: 2.401

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Cooperative systematic studies of rheumatic diseases.

Authors:  H J Williams; J R Ward; M J Egger; J C Reading; C O Samuelson; M Altz-Smith; R W Willkens; M A Solsky; S P Hayes; D Furst
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.